Digital PNG artwork · delivered by email | Secure checkout · no physical shipping
Hedi Raizer

Journal 5 min read

What is KPV?

KPV is the endogenous tripeptide lysine-proline-valine, a fragment of alpha-melanocyte-stimulating hormone studied in laboratory models of inflammation, adipogenesis and hepatic lipid handling.

peptides-pro Editorial

KPV is the tripeptide lysine-proline-valine, also written Lys-Pro-Val and referred to in the literature as an endogenous tripeptide derived from alpha-melanocyte-stimulating hormone (alpha-MSH) [2][3]. It is classified as a peptide, and in laboratory work it appears both as the free tripeptide and as a conjugated cargo in engineered delivery systems [1]. The evidence block for this page does not supply a full sequence string, molecular formula or molecular weight for KPV, so none are stated here.

The work described in the available evidence centres on reactive oxygen species (ROS)-dependent signalling, with the PPARgamma pathway and the AKT/mTORC1 axis named as the downstream elements examined in cell and adipocyte models [2][3].

KPV is supplied by lysine-proline-valine for laboratory research use only.

Research Studies

KPV and oral peptide delivery across gastrointestinal barriers

Oral delivery of peptide therapeutics is limited by degradation in the gastrointestinal tract and poor absorption across the intestinal epithelium. A self-immolative peptide prodrug conjugate (SIPPC) platform was developed to address both problems at once, combining a hydrophilic polyethylene glycol segment, a reactive oxygen species-responsive hydrophobic self-immolative module, and a hydrolyzable scaffold. The components assemble spontaneously into micelle-like nanoparticles [1].

KPV was one of three anti-inflammatory peptides used to test the platform, alongside Ac-QAW and IRW. The engineered conjugates were reported to show gastrointestinal stability, mucus penetration, and ROS-responsive release at sites of inflammation [1]. This is a formulation and delivery finding; it describes the behaviour of a conjugate system rather than the pharmacology of unmodified KPV.

KPV and adipogenesis in differentiating adipocytes

KPV has been recognised for anti-inflammatory and antioxidant activity, but its role in adipocyte differentiation had not been investigated before the study summarised here. That work examined the regulatory effects of KPV on MDI-induced differentiation and on lipid metabolism, and reported attenuation of adipogenesis through modulation of ROS-mediated AKT/mTORC1/PPARgamma signalling [2].

The finding is attributed to a cell-based adipocyte differentiation model. It identifies a signalling route rather than establishing an in vivo effect.

KPV and hepatic lipid accumulation in HepG2 cells

Hepatocellular steatosis is an early stage within the non-alcoholic fatty liver disease spectrum and is characterised by excessive lipid accumulation and oxidative stress in hepatocytes. A study using HepG2 cells examined the protective role of KPV, the endogenous tripeptide derived from alpha-MSH, in that setting [3].

The reported result was attenuation of hepatic lipid accumulation through ROS-dependent regulation of the PPARgamma pathway [3]. As with the adipocyte work, the model is a cultured cell line, so the observation is in vitro.

KPV and the PPARgamma pathway across two cell models

Two of the studies in this evidence block converge on PPARgamma, but they do so in different cell types and with different upstream emphasis. The table below sets the two side by side.

ModelProcess examinedSignalling reported
Differentiating adipocytes (MDI-induced)Adipogenesis and lipid metabolismROS-mediated AKT/mTORC1/PPARgamma [2]
HepG2 hepatocytesHepatic lipid accumulationROS-dependent PPARgamma [3]

Both entries are cell-based. Neither table row should be read as a whole-organism result.

KPV and ROS-responsive release at inflamed tissue

The SIPPC platform was designed around the assumption that inflamed tissue presents a distinct chemical environment, specifically one with elevated reactive oxygen species. The self-immolative module was built to respond to that environment, releasing cargo when ROS levels are high [1].

KPV served as one of the three peptide cargos used to demonstrate the concept. The reported outcomes were gastrointestinal stability, mucus penetration and ROS-responsive release at inflammation sites [1]. The design logic is therefore conditional: release depends on the local ROS profile of the tissue being studied.

KPV and gastrointestinal stability as a formulated conjugate

Peptides are vulnerable to gastrointestinal degradation, which is one of the two barriers the SIPPC work set out to overcome; the other was poor intestinal absorption [1]. The conjugate approach places the peptide inside a micelle-like nanoparticle assembly rather than exposing it directly to the gut environment.

In the reported experiments, the KPV-bearing conjugates were stable in the gastrointestinal setting and penetrated mucus [1]. This describes the behaviour of the conjugate, not of free KPV administered orally.

KPV and host defense peptides in inflammatory bowel disease research

Inflammatory bowel diseases are chronic disorders of the gastrointestinal tract characterised by severe inflammation and tissue damage, and existing treatments carry adverse effects that motivate the search for alternatives. A short review of host defense peptides (HDPs) positions this class as a promising drug lead for inflammatory bowel disease [5].

KPV belongs to the broader peptide space that this review surveys. The review is a discussion of the class and its therapeutic potential, not a report of a trial in patients.

KPV and peptide use in sport: what the critical review covers

A critical review examined the shift in pharmacological enhancement in sport from anabolic-androgenic steroids toward peptides and peptide analogues, which are marketed as more selective and ostensibly safer alternatives. The agents discussed include growth hormone secretagogues such as ipamorelin and growth hormone-related peptides [4].

This review is included here because it documents the commercial and cultural context in which research peptides circulate. It is not a study of KPV, and no KPV-specific finding should be drawn from it.

KPV and the limits of the current evidence

Across the studies summarised above, the KPV-specific findings come from cultured cell models and from engineered conjugate systems [1][2][3]. The adipogenesis and hepatic lipid work is in vitro [2][3]. The oral delivery work reports formulation performance in the gastrointestinal tract and at inflamed tissue [1].

No clinical endpoint, human dose, or whole-organism outcome for KPV is reported in this evidence block. Where a mechanism is named, it is named as it was observed in the model used, and the model is stated alongside it.

If you are reading this for personal health reasons

This material is sold for laboratory research only, and we do not provide dosing or medical guidance. Anyone considering a compound for themselves should speak to a licensed clinician.

Sources

WhatsApp